Synthesis and Structure-Activity Relationship of Novel, Highly Potent Metharyl and Methcycloalkyl Cyclooxygenase-2 (COX-2) Selective Inhibitors

Journal of Medicinal Chemistry

Volumn 46, Issue 25, 2003, Pages 5484-5504

  Khanapure, Subhash P ^a   Shumway, Matthew ^a   Trocha, Mark ^a   Marek, Przemyslaw ^a   William Tam, S ^a   Janero, David R ^a   Gordon Letts, L ^a   Garvey, David S ^a   Young, Delano V ^a   Ezawa, Maiko ^a   Earl, Richard A ^a   Gaston, Rick D ^a   Fang, Xinqin ^a   Murty, Madhavi ^a   Martino, Allison ^a  

^a NitroMed Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [6 (CYCLOHEXYLMETHYL)(2H BENZO[3,4 D] 1,3 DIOXOLAN 5 YL)] 4 (METHYLSULFONYL)BENZENE; 1 [6 [(4 FLUOROPHENYL)METHYL](2H BENZO[3,4 D] 1,3 DIOXOLOLAN 5 YL)] 4 (METHYLSULFONYL)BENZENE; 2H BENZO[3,4 D] 1,3 DIOXOLAN 5 YL 1 (METHYLSULFONYL)BENZENE; 3 FLUOROPHENYL 6 [4 (METHYLSULFONYL)PHENYL](2H BENZO[D] 1,3 DIOXOLAN 5 YL)KETONE; 3 METHYLPHENYL 6 [4 (METHYLSULFONYL)](2H BENZO[D] 1,3 DIOXOLAN 5 YL)KETONE; 4 [6 (CYCLOPENTYLIDENEMETHYL)(2H BENZO[3,4 D] 1,3 DIOXOLAN 5 YL)] 1 (METHYLSULFONYL)BENZENE; ALKYL GROUP; CARBENE; CARBONYL DERIVATIVE; CYCLOHEXYL 6 [4 [9 (METHYLSULFONYL)PHENYL](2H BENZO[D] 1,3 DIOXOLAN 5 YL)KETONE]; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; METHYL GROUP; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYCLOPARAFFINS; DIOXOLANES; FEMALE; HUMANS; INFLAMMATION; ISOENZYMES; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 10744221217     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030268b     Document Type: Article

References (57)

1. Vane, J. R.; Botting, R. M. Therapeutic Roles of Selective COX-2 Inhibitors; William Harvey Press: London, UK, 2001; pp 1-548.
2. Ford-Hutchinson, A. W. Evidence for the Involvement of Leukotrienes and Other Lipoxygenase Products in Disease States. Chapter 5. Leukotrienes and Lipoxygenases: Chemical, Biological and Clinical Aspects; Rokach, J., Ed.; Elsevier Press: Amsterdam, 1989; pp 407-410.
3. Jones, T. R.; Letts, G.; Chan, C.; Davies, P. Pharmacology and Pathophysiology of Leukotrienes. Leukotrienes and Lipoxygenases, Chemical, Biological and Clinical Aspects, 1st ed.; Rokach, J., Ed.; Elsevier Science: Amsterdam, The Netherlands, 1989; pp 309-403, p 333.
4. Ford-Hutchinson, A. W. Leukotriene B4 in Inflammation. Crit. Rev. Immunol. 1990, 10, 1-12.
5. Wang, S.; Gustafson, E.; Pang, L.; Qiao, X.; Behan, J.; Maguire, M.; Bayne, M.; Laz, T. A Novel Hepatointestinal Leukotriene B4 Receptor. Cloning and Functional Charcterization. J. Biol. Chem. 2000, 275, 40686-40694.
6. 2. J. Biol. Chem. 2001, 276, 12454-12459.
7. Geng, Y.; Blanco, F. J.; Cornellison, M.; Lotz, M. Regulation of Cyclooxygenase-2 Expression in Normal Human Articular Chondrocytes. J. Immunol. 1995, 155, 796-801.
8. Chan, C.-C.; DiBattista, J. A.; Zhao, J.; Pelletier, J.-P.; Martel-Pelletier, J.; Kennedy, B. P.; Brideau, C.; Rodger, I. W. Induction of Cyclooxygenase-2 (COX-2) in Human Articular Chondrocytes and Inhibition of PGE2 Synthesis by a Selective COX-2 Inhibitor; International Association of Inflammation Society: Brighton, 1995; pp S275.
9. Turini, M. E.; DuBois, R. N. Cyclooxygenase-2: A Therapeutic Target. Annu. Rev. Med. 2002, 53, 35-57.
10. Dannhardt, G.; Kiefer, W. Cyclooxygenase Inhibitors-Current Status and Future Prospects. Eur. J. Med. Chem. 2001, 36, 109-126.
11. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogers, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
12. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C. C.; Charleson, S.; Cromilish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Gyay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Parcival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Tagari, P.; Therien, M.; Vickers, P.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R. The Discovery of Rofecoxib, {MK 966, Vioxx, 4-(4-Methylsulfonylphenyl)3-Phenyl-2(5H)-Furanone], An Orally Active Cyclooxygenase-2 Inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
13. Chan, C.-C.; Bouce, S.; Brideau, C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J.; Ford-Hutchinson, A. W.; Forrest, M. J.; Gauthier, J. Y.; Gordon, R.; Gresser, M.; Guay, J.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'neill, G. P.; Ouellet, M.; Patrick, D.; Percival, M. D.; Perrier, H.; Prasit, P.; Rodger, I.; Tagari, P.; Therien, M.; Vickers, P.; Visco, D.; Wang, Z.; Webb, J.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R.; Riendeau, D. Rofecoxib [Vioxx, MK-0966; 4-(4′ -Methylsulfonylphenyl)-3phenyl-2-(5H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles. J. Pharmacol. Exp. Ther. 1999, 290, 551-560.
14. FitzGerald, G. A.; Patrono, C. The Coxibs, Selective Inhibitors of Cyclooxygenase-2. N. Engl. J. Med. 2001, 345, 433-442.
15. Jackson, L. M.; Hawkey, C. J. Gastrointestinal Effects of COX-2 Inhibitors, Exp. Opin. Invest. Drugs 1999, 8, 963-971.
16. Yuan, J. J.; Zhang, D.-C. Y. J. Y.; Jr., R. B.; Karim, A.; Findlay, J. W. A. Disposition of a Specific Cyclooxygenase-2 Inhibitor, Valdecoxib, in Human. Am. Soc. Pharmacol. Exp. Ther. 2002, 30, 1013-1021.
17. Talley, J. A.; Brown, D. L.; Carter, J. S.; Masferrer, M. J.; Perkins, W. E.; Rogers, R. S.; Shaffer, A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seibert, K. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzene-sulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2. J. Med. Chem. 2000, 43, 775-777.
18. Hashimoto, H.; Imamura, K.; Haruta, J.; Wakitani, K. 4-(4-Cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as Selective Cyclooxygenase-2 Inhibitors: Enhancement of the Selectivity by Introduction of a Fluorine Atom and Identification of a Potent, Highly Selective, and Orally Active COX-2 Inhibitor JTE-522. J. Med. Chem. 2002, 45, 1511-1517.
19. Drugupdates, R & D Focus June 3, 2002.
20. Gans, K. R.; Galbraith, W.; Romans, R. J.; Haber, S. B.; Kerr, J. S.; Schmidt, W. K.; Smith, C.; Hewes, W. E.; Ackerman, N. R. Antiinflammatory and Safety Profile of DuP 697, a Novel Orally Effective Prostaglandin Synthesis Inhibitor. J. Pharmacol. Exp. Ther. 1990, 254, 180-187.
21. Galbraith, R. DuP 697 as an Agent which may be a Selective Cyclooxygenase Inhibitor. Winter Prostaglandin Conference; Keystone, CO, January 1992; pp Abs.
22. Futaki, N.; Yoshikawa, K.; Hamasaka, Y.; Arai, I.; Higuchi, S.; Iizuka, H.; Otomo, S. NS-398, a Novel Non-Steroidal Antiinflammatory Drug with Potent Analgesic and Antipyretic Effects, shich Causes Minimal Stomach Lesions. Gen. Pharmacol. 1993, 24, 105-110.
23. Futaki, N.; Takahashi, S.; Yokoyama, M.; Arai, I.; Higuchi, S.; Otomo, S. NS-398, a New Antiinflammatory Agent, Selectively Inhibits Prostaglandin G/H Synthase/Cyclooxygenase (COX-2) Activity in Vitro. Prostaglandins 1994, 47, 55-59.
24. Copeland, R. A.; Williams, J. M.; Giannaras, J.; Nurnberg, S.; Covington, M.; Pinto, D. Mechanism of Selective Inhibition of the Inducible Isoform of Prostaglandin G/H Synthase. Proc. Natl. Acad. Sci. 1994, 91, 11202-11206.
25. Marnett, L. J.; Rowlinson, S. W.; Goodwin, D. C.; Kalgutkar, A. S.; Lanzo, C. A. Arachidonic Acid Oxygenation by COX-1 and COX-2; Mechanisms of Catalysis and Inhibition. J. Biol. Chem. 1999, 274, 22903-22906.
26. Kiefer, J. R.; Pawlitz, J. L.; Moreland, K. T.; Stegeman, R. A.; Hood, W. F.; Gierse, J. K.; Stevens, A. M.; Goodwin, D. C.; Rowlinson, S. W.; Marnett, L. J.; Stallings, W. C.; Kurumbail, R. G. Structural Insights into the Stereochemistry of the Cyclooxygenase Reaction. Lett. Nature 2000, 405, 97-101.
27. Kurumbali, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural Basis for Selective Inhibition of Cyclooxygenase-2 by Inflammatory Agents. Nature 1996, 384, 644-648.
28. 2 Synthase-1. Nature 1994, 367, 243-249.
29. Dannhardt, G.; Laufer, S. Structural Approaches to Explain the Selectivity of COX-2 Inhibitors: Is there a Common Pharmacophore? Curr. Med. Chem. 2000, 7, 1101-1112.
30. Ochi, T.; Goto, T. Antiinflammatory Effect of FR140423, a Novel Slective Cyclooxygenase-2 Inhibitor, in Rat Adjuvant Arthritis Without Gastrointestinal Side Effects. J. Pharmacokinet. Pharmacol. 2000, 52, 553-560.
31. Reitz, D. B.; Li, J. L.; Norton, M. B.; Reinhard, E. J.; Collins, J. T.; Anderson, G. D.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Isakson, P. C. Slective Cyclooxygenase Inhibitors: Novel 1, 2-Diarylcyclopentenes Are Potent and Orally Active COX-2 Inhibitors. J. Med. Chem. 1994, 37, 3878-3881.
32. Li, J. J.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Collins, J. T.; Garland, D. J.; Gregory, S. S.; Huang, H.-C.; Isakson, P. C.; Koboldt, C. M.; Logusch, E. W.; Norton, M. B.; Perkins, W. E.; Reinhard, E. J.; Seibert, K. ; Veenhuizen, A. W.; Zhang, Y.; Reitz, D. B. 1,2-Diarylcyclopentenes as Selective Cyclooxygenase-2 Inhibitors and Orally Active Antiinflammatory Agents. J. Med. Chem. 1995, 38, 4570-4578.
33. Black, W. C.; Brideau, C.; Chan, C.; Charleson, S.; Chauret, N.; Claveau, D.; Ethier, D.; Gordon, R.; Greig, G.; Guay, J.; Hughes, G.; Jolicoeur, P.; Leblanc, Y.; Nicoll-Griffith, D.; Quimet, N.; Riendeau, D.; Visco, D.; Wang, Z. ; Xu, L.; Prasit, P. 2,3-Diarylcyclopentenones as Orally Active, Highly Selective Cyclooxygenase-2 Inhibitors. J. Med. Chem. 1999, 42, 1274-1281.
34. Khanna, I. K.; Huff, Y. Y. R. M.; Weier, R. M.; Xu, X.; Koszyk, F. J.; Collins, P. W.; Cogburn, J. N.; Isakson, P. C.; Koboldt, C. M.; Masferrer, J. L.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Yuan, J.; Yang, D.; Zhang, Y. Y. Selective Cyclooxygenase-2 Inhibitors: Heteroaryl Modified 1,2-Diarylimidazoles are Potent, Orally Active Antiinflammatory Agents. J. Med. Chem. 2000, 43, 3168-3185.
35. Khanna, I. K.; Weier, R. M.; Xiang, Y. Y.; Xu, D.; Koszyk, F. J.; Collins, P. W.; Koboldt, C. M.; Veenhuizen, A. W.; Perkins, W. E.; Casler, J. J.; Masferrer, J. L.; Zhang, Y. Y.; Gregory, S. A.; Seibert, K.; Isakson, P. C. 1,2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective, and Orally Active Antiinflammatory Agents. J. Med. Chem. 1997, 40, 1634-1647.
36. Khanna, I. K.; Weier, R. M.; Yu, Y.; Collins, P. W.; Miyashiro, J. M.; Koboldt, C. M.; Veenhuizen, A. W.; Currie, J. L.; Seibert, K.; Isakson, P. C. 1,2-Diarylpyrroles as Potent and Selective Inhibitors of Cyclooxygenase-2. J. Med. Chem. 1997, 40, 1619-1633.
37. Matsushita, M.; Masaki, M.; Yagi, Y.; Tanaka, T.; Wakitani, K. Pharmacological Profile of JTE-522, A Novel Prostaglandin H Synthase-2 Inhibitor, in Rats. Inflamm. Res. 1997, 46, 461-466.
38. Puig, C.; Crespo, M. I.; Godessart, N.; Feixas, J.; Ibarzo, J.; Jimenez, J.; Soca, L.; Cardelus, I.; Heredia, A.; Miralpeix, M.; Puig, J.; Beleta, J.; Huerta, J. M.; Lopez, M.; Segarra, V.; Ryder, H.; Palacios, J. M. Synthesis and Biological Evaluation of 3,4-Diaryloxazolones: A New Class of Orally Active Cyclooxygenase-2 Inhibitors. J. Med. Chem. 2000, 43, 214-223.
39. Huang, H.-C.; Li, J. J.; Garland, D. J.; Chamberlain, T. S.; Reinhard, E. J.; Manning, R. E.; Seibert, K.; Koboldt, C. M.; Anderson, S. A. G. G. D.; Veenhuizen, A. W.; Zhang, Y.; Perkins, W. E.; Burton, E. G.; Cogburn, J. N.; Isakson, P. C.; Reitz, D. B. Diarylspiro[2.4]heptenes as Orally Active, Highly Selective Cyclooxygenase-2 Inhibitors: Synthesis and Structure-Activity Relationships. J. Med. Chem. 1996, 39, 253-266.
40. Li, J. J.; Norton, M. B.; Reinhard, E. J.; Anderson, G. D.; Gregory, S. A.; Isakson, P, C.; Koboldt, C. M.; Masferrer, J. L.; Perkins, W. E.; Seibert, K.; Zhang, Y.; Zweifel, B. S.; Reitz, D. B. Novel Terphenyls as Selective Cyclooxygenase-2 Inhibitors and Orally Active Antiinflammatory Agents. J. Med. Chem. 1996, 39, 1846-1856.
41. Davies, I. W.; Marcoux, J.-F.; Corley, E. G.; Journet, M.; Cai, D.-W.; Palucki, M.; Wu, J.; Larsen, R. D.; Rossen, K.; Pye, P. J.; DiMichele, L.; Dormer, P.; Reider, P. J. A Practical Synthesis of a COX-2 Specific Inhibitor. J. Org. Chem. 2000, 65, 8415-8420.
42. Davies, I. W.; Taylor, M.; Marcoux, J.-F.; Wu, J.; Dormer, P. G.; Hughes, D.; Reider, P. J. Preparation and Novel Reduction Reactions of Vinamidinium Salts. J. Org. Chem. 2001, 66, 251-255.
43. Li, C.-S.; Black, W. C.; Chan, C.-C.; Ford-Hutchinson, A. W.; Gauthier, J.-Y.; Gordon, R.; Guay, D.; Kargman, S.; Lau, C. K.; Mancini, J.; Quimet, N.; Roy, P.; Vickers, P.; Wong, E.; Young, R. N.; Prasit, P. Cyclooxygenase-2 Inhibitors. Synthesis and Pharmacological Activities of 5-Methanesulfonamido-1-Indanone Derivatives. J. Med. Chem. 1995, 38, 4897-4905.
44. Almansa, C.; Arriba, A. F. D.; Cavalcanti, F. L.; Gomez, L. A.; Miralles, A.; Merlos, M.; Garcia-Rafanell, J.; Forn, J. Synthesis and SAR of a New Series of COX-2 Selective Inhibitors: Pyrazolo[1,5-a]pyrimidines. J. Med. Chem. 2001, 44, 350-361.
45. Kalgutkar, A. S.; Marnett, A. B.; Crews, B. C.; Remmel, R. P.; Marnett, L. J. Ester and Amide Derivatives of the Nonsteroidal Antiinflammatory Drug, Indomethacin, as Selective Cyclooxygenase-2 Inhibitors. J. Med. Chem. 2000, 43, 2860-2870.
46. Bayly, C. I.; Black, W. C.; Leger, S.; Ouimet, N.; Ouellet, M.; Percival, M. D. Structure-Based Design of COX-2 Selectivity into Flurbiprofen. Bioorg. Med. Chem. Lett. 1999, 9, 307-312.
47. Desiraju, G. R.; Gopalakrishnan, B.; Jetti, R. K. R.; Nagaraju, A.; Raveendra, D.; Sarma, J. A. R. P.; Sobhia, M. E.; Thilagavathi, R. Computer-Aided Design of Selective COX-2 Inhibitors: Comparative Molecular Field Analysis, Comparative Molecular Similarity Indices Analysis, and Docking Studies of Some 1,2-Diarylimidazole Derivatives. J. Med. Chem. 2002, 45, 4847-4857.
48. Liu, H.; Huang, X.; Shen, J.; Luo, X.; Li, M.; Xiong, B.; Chen, G.; Shen, J.; Yang, Y.; Jiang, H.; Chen, K. Inhibitory Mode of 1,5-Diarylpyrazole Derivatives against Cyclooxygenase-2 and Cyclooxygenase-1: Molecular Docking and 3D QSAR Analyses. J. Med. Chem. 2002, 45, 4816-4827.
49. Chavatte, P.; Yous, S.; Marot, C.; Baurin, N.; Lesieur, D. Three-Dimensional Quantitative Structure-Activity Relationships of Cyclooxygenase-2 (COX-2) Inhibitors: A Comparative Molecular Field Analysis. J. Med. Chem. 2001, 44, 3223-3230.
50. Khanapure, S. P.; Biehl, E. R. Synthesis of Novel 4-Substituted Derivatives of 6-Methoxy, 6,7-Dimethoxy- and 6,7-(Methylene-dioxy)isochroman-3-ones. Part II. J Org. Chem. 1990, 55, 1471-1475.
51. Miyaura, M.; Yanagi, T.; Suzuki, A. The Palladium-Catalyzed Cross-Coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of Bases. Synth. Commun. 1981, 11, 513-519.
52. Lages, A. S.; Silva, K. C. M.; Miranda, A. L. P.; Fraga, C. A. M.; Barreiro, E. J. Synthesis and Pharmacological Evaluation of New Flosulide Analogues, Synthesized from Natural Safrole. Bioorg. Med. Chem. Lett. 1998, 8, 183-188.
53. Robins, M. R.; Wnuk, S. F. Efficient Conversion of Thioethers to α-Fluoro Thioethers with DAST or DAST/Antimony(III) Chloride. J. Org. Chem. 1993, 58, 3800-3801.
54. Lee, L. F.; Bertenshaw, S. R. 1,5-Diphenyl Pyrazole Compounds for the Treatment of Inflammation. In PCT Application WO 95/15315; G. D. Searle & Co., US, June 8, 1995.
55. Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; Dube, D.; Ethier, D.; Falgueyret, J.-P.; Friesen, R. W.; Gordon, R.; Greig, G.; Guay, J.; Manacini, J.; Ouellet, M.; Wong, E.; Xu, L.; Boyce, S.; Visco, D.; Girad, Y.; Prasit, P.; Zamboni, R.; Rodger, I. W.; Gresser, M.; Ford-Hutchinson, A. W.; Young, R. N.; Chan, C.-C. Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2. J. Pharmacol. Exp. Ther. 2001, 296, 558-566.
56. 2 Production. Inflamm. Res. 1996, 45, 246-253.
57. Masferrer, J. L.; Zweifel, B. S.; Manning, P. T.; Hauser, S. D.; Leahy, K. M.; Smith, W. G.; Isakson, P. C.; Seibert, K. Inhibition of Inducible Cyclooxygenase-2 in vivo is antiinflammatory and Nonulcerogenic. Proc. Natl. Acad. Sci. 1994, 91, 3228-3232.